FindTrial
Sign In

CYLD mRNA m6A methylation promotes endothelial dysfunction in ARDS mediated by mitochondrial DNA

CYLD mRNA m6A methylation promotes endothelial dysfunction in ARDS mediated by mitochondrial DNA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056705
Enrollment
Unknown
Registered
2022-02-10
Start date
2022-02-10
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome (ARDS)

Interventions

None listed

Sponsors

Zhongda Hospital, School of Medicine, Southeast University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed of ARDS; Patients admitted to ICU for more than 24 hours; Patients with informed consent

Exclusion criteria

Exclusion criteria: Patients age less than 18 years old or more than 80 years old; Patients with acute and chronic hepatitis or cirrhosis or liver transplantation. Patients with acute myocardial infarction; Pregnant patients or tumor patients; Patients with immune deficiency disease; Patients had extensive use of glucocorticoids (equivalent dose >Prednisone 10mg/d) or immunosuppressant 6 months before admission.

Design outcomes

Primary

MeasureTime frame
28 Day Outcome;—

Countries

China

Contacts

Public ContactMeng Shanshan

Zhongda Hospital, School of Medicine, Southeast University

mengshanshan0101@163.com13705171687

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026